Rodney Bates, MD
Family Medicine · Stanford, KYNPI 1477596542
Payments from drug & device makers
Across 148 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$436
- Lilly USA, LLC$327
- Sanofi-aventis U.S. LLC$200
- Pfizer$116
- Johnson & Johnson$113
- GSK$111
- plus $941 from 24 others
What the payments were for
- Food & beverage$2,243100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $436 |
| Lilly USA, LLC | 22 | $327 |
| Sanofi-aventis U.S. LLC | 15 | $200 |
| Pfizer | 9 | $116 |
| Johnson & Johnson | 7 | $113 |
| GSK | 7 | $111 |
| Amgen | 6 | $100 |
| AstraZeneca | 8 | $100 |
| Boehringer Ingelheim | 7 | $89 |
| Esperion Therapeutics, Inc. | 5 | $75 |
| Novartis | 5 | $66 |
| Abbott | 3 | $60 |
| Medtronic | 3 | $59 |
| E.r. Squibb & Sons, L.L.C. | 4 | $58 |
| Astellas Pharma US Inc | 3 | $50 |
| Merck | 3 | $48 |
| Novo Nordisk | 2 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $24 |
| Amarin Pharma, Inc. | 2 | $23 |
| Shield Therapeutics Inc | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Biogen | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Agile Therapeutics, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Sobi, Inc | 1 | $12 |
| Genentech USA, Inc. | 1 | $11 |
| Axsome Therapeutics, Inc. | 1 | $10 |
How this compares
$2,243 in reported general payments places this provider in the 70th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 90 | $102,981 |
| EliquisApixaban | 70 | $85,855 |
| JanuviaSitagliptin Phosphate | 49 | $51,340 |
| TrulicityDulaglutide | 22 | $39,239 |
| XareltoRivaroxaban | 43 | $38,578 |
| Repatha SureclickEvolocumab | 40 | $28,099 |
| EntrestoSacubitril/Valsartan | 31 | $26,259 |
| MyrbetriqMirabegron | 27 | $26,234 |
| VascepaIcosapent Ethyl | 29 | $22,673 |
| OzempicSemaglutide | 25 | $22,439 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $19,086 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $14,215 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $12,701 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,721 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $10,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $89 | $102,98190 claims |
| PfizerEliquis, Dilantin, Premarin | $116 | $93,82098 claims |
| MerckJanuvia, Janumet Xr | $48 | $65,55563 claims |
| Lilly USA, LLCTrulicity | $327 | $39,23922 claims |
| Johnson & JohnsonXarelto | $113 | $38,57843 claims |
| NovartisEntresto | $66 | $26,25931 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $26,23427 claims |
| Novo NordiskOzempic | $25 | $22,43925 claims |
| GSKTrelegy Ellipta | $111 | $10,72115 claims |
| AstraZenecaSymbicort | $100 | $5,99413 claims |
| AbbVieSynthroid | $436 | $3,08056 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Stanford
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.